The company's gene-editing-focused platform looks promising.

Billionaire investor Cathie Wood, through her ARK ETFs, made big buys of CRISPR Therapeutics on Friday, Oct. 9, and Monday, ...

CRISPR Therapeutics (NasdaqGM:CRSP) has promoted Andrew J. Silver to Chief Financial Officer, effective October 19, 2026.

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $49.89, moving 1.21% from the previous trading session.

Spread the loveImagine looking in the mirror and seeing a younger version of yourself, not just cosmetically, but at a ...

Human cells hold about two meters (6.6 feet) of DNA, folded and compacted to fit inside a nucleus. That packing is essential ...

Application of the high-precision technique is part of a clinical trial to treat a genetic disease that can cause liver and ...

Nurtured Nuts is using CRISPR-edited peanuts to rethink peanut butter, but what that means for people with peanut allergies ...

Late last month, Anthropic claimed it had discovered a curious stretch of DNA in a virus called a bacteriophage that repeats ...

The company's expertise in gene editing could lead to more breakthroughs.

CRISPR pioneer Jennifer Doudna on the evolution of gene-editing technology, her own path, and what it takes to be a good scientist.

Experts at the company don't know what the newfound system does, so its potential utility in biology—if any—remains unclear. But the work marks a major advancement because the A.I. made this discovery ...